Inventor · disambiguated record
Ryan Bjordahl
Also filed as: BJORDAHL RYAN
18 granted patents·14 pending applications·122 citations·filing 2016–2025
94Inventor score
Files withFATE THERAPEUTICS INC32
Top patents by PatentIndex Score
32 records- 0198US10947505B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2020·Granted Mar 16, 2021·8 cites·20 claims
- 0297US11365394B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2021·Granted Jun 21, 2022·14 cites·20 claims
- 0397US11162076B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2021·Granted Nov 2, 2021·7 cites·29 claims
- 0497US11162075B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2020·Granted Nov 2, 2021·5 cites·10 claims
- 0596US10927346B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2019·Granted Feb 23, 2021·17 cites·22 claims
- 0696US10858628B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2016·Granted Dec 8, 2020·15 cites·25 claims
- 0796US10287606B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2017·Granted May 14, 2019·28 cites·24 claims
- 0895US11072781B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2019·Granted Jul 27, 2021·18 cites·18 claims
- 0989US11413309B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2017·Granted Aug 16, 2022·4 cites·26 claims
- 1089US11096964B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2017·Granted Aug 24, 2021·4 cites·31 claims
- 1187US11352607B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2019·Granted Jun 7, 2022·2 cites·28 claims
- 1278US12410403B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2021·Granted Sep 9, 2025·0 cites·20 claims
- 1375US12173274B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2021·Granted Dec 24, 2024·0 cites·22 claims
- 1473US12419870B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2022·Granted Sep 23, 2025·0 cites·16 claims
- 1573US12398373B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2018·Granted Aug 26, 2025·0 cites·26 claims
- 1673US2025145966A1Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1772US12281329B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2021·Granted Apr 22, 2025·0 cites·27 claims
- 1872US2021324340A1Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1970US2025215396A1Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2069US12275955B2Combining iPSC derived effector cell types for immunotherapy useFATE THERAPEUTICS INC·Filed 2021·Granted Apr 15, 2025·0 cites·40 claims
- 2163US2025313802A1Combining ipsc derived effector cell types for immunotherapy useFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2261US2021163622A1Immune effector cell engineering and use thereofFATE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2360US12435123B2Immunotherapies using enhanced iPSC derived effector cellsFATE THERAPEUTICS INC·Filed 2019·Granted Oct 7, 2025·0 cites·28 claims
- 2460US2025018034A1Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumorsFATE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2559US2022275333A1Immune effector cell engineering and use thereofFATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2657US2024307540A1Protected effector cells and use thereof for allogeneic adoptive cell therapiesFATE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2753US2023016034A1ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDSFATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2852US2024115602A1Enhanced chimeric antigen receptor for immune effector cell engineering and use thereofFATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2952US2024226293A9Enhanced chimeric antigen receptor for immune effector cell engineering and use thereofFATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3052US2022378831A1Multi-targeting effector cells and use thereofFATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3148US2021015859A1IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLSFATE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3248US2021024959A1Engineered immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ryan Bjordahl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →